NICE back Roche’s Tecentriq for CDF

1st November 2017 Uncategorised 0

The National Institute for Health and Care Excellence is recommending Roche’s Tecentriq for use within the Cancer Drugs Fund to treat advanced urothelial cancer in certain circumstances.

More: NICE back Roche’s Tecentriq for CDF
Source: News